...
首页> 外文期刊>Experimental and therapeutic medicine >Development and evaluation of LAMP, CPA and IMSA methods for rapid detection of the AML1/ETO fusion gene in acute myeloid leukemia
【24h】

Development and evaluation of LAMP, CPA and IMSA methods for rapid detection of the AML1/ETO fusion gene in acute myeloid leukemia

机译:灯,CPA和IMSA方法快速检测急性髓性白血病AML1 / ETO融合基因的开发和评价

获取原文
获取原文并翻译 | 示例
           

摘要

The objective of the present study was to determine whether the loop-mediated isothermal amplification (LAMP), cross-priming amplification (CPA), and/or isothermal multiple-self-matching-initiated amplification (IMSA) methods can provide rapid detection of the runt related transcription factor 1/runt related transcription factor 1 translocation partner 1 (AML1/ETO) fusion gene in acute myeloid leukemia (AML). According to the sequence of the AML1/ETO fusion gene available in GenBank and the principles of the LAMP, CPA and IMSA methods, specific primers were designed to bind a conserved region of the AML1/ETO gene in each assay. Following optimization of the conditions for the LAMP, CPA and IMSA assays, the specificity and sensitivity of the assays were examined and compared. In addition, 41 clinical samples were assayed using the three methods. It was observed that a ladder-like pattern of DNA products was produced in AML1/ETO-positive samples in all three assays, whereas no DNA product was generated with the controls. The detection limit of the LAMP and CPA assays was 50 copies/tube, and for the IMSA assay was 10 copies/tube. This sensitivity was consistent, and improved in the latter case, compared with that of the reverse transcription-polymerase chain reaction (RT-PCR) assay. Furthermore, the detection rate for bone marrow or peripheral blood samples was 9.76%, and the agreement among the LAMP, CPA, IMSA and RT-PCR methods was 100%. Therefore, the LAMP, CPA and IMSA methods optimized in the present study provided rapid detection of the AML1/ETO fusion gene for an initial clinical diagnosis of AML. In addition, the LAMP, CPA and IMSA assays are straightforward to perform and do not require specialized instruments. Therefore, these three isothermal methods may be used to perform field tests or assays at resource-limited hospitals.
机译:本研究的目的是确定环介导的等温扩增(灯),交叉引发扩增(CPA)和/或等温多匹配引发的扩增(IMSA)方法可以快速检测Runt相关转录因子1 / runt相关转录因子1易患骨髓白血病(AML)中的易位伴侣1(AML1 / ETO)融合基因。根据Genbank中可用的AML1 / EtO融合基因的序列和灯,CPA和IMSA方法的原理,设计了特异性引物以在每个测定中结合AML1 / EtO基因的保守区域。在优化灯泡,CPA和IMSA测定的条件下,检查测定的特异性和灵敏度并进行比较。此外,使用三种方法测定41个临床样品。观察到,在所有三种测定中,在AML1 / EtO阳性样品中在AML1 / EtO阳性样品中产生梯状的DNA产品图案,而没有对照组产生DNA产物。灯和CPA测定的检测限为50份/管,并且对于IMSA测定为10份/管。与逆转录聚合酶链反应(RT-PCR)测定相比,这种敏感性在后一种情况下是一致的,并且在后一种情况下得到改善。此外,骨髓或外周血样品的检出率为9.76%,灯泡,CPA,IMSA和RT-PCR方法之间的协议为100%。因此,在本研究中优化的灯,CPA和IMSA方法提供了快速检测AML1 / ETO融合基因,用于AML的初始临床诊断。此外,灯泡,CPA和IMSA测定是简单的,不需要专门的仪器。因此,这三种等温方法可用于在资源有限医院进行现场测试或分析。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号